



While attending the AMMI Canada – CACMID Annual Conference, you are cordially invited to attend an AMMI Canada / Sunovion Pharmaceuticals Canada Co-developed Accredited Learning Activity

## IS IT TIME TO REPLACE VANCOMYCIN?

The focus of the program is to discuss the utility and future of vancomycin in the treatment of complicated MRSA infections. While considered to be the “gold standard”, vancomycin is not without its issues. There are many who question its effectiveness, tolerability, safety and recommended dosing regimens. Throughout the years, there have been reports of increasing MICs and some considerable debate surrounding the most effective methodology for susceptibility testing. During the last decade we have seen the arrival of newer agents to treat complicated MRSA infections. While more convenient, these newer agents have never proven superior to the gold standard but is it time to consider these newer agents as empiric therapy given the issues that have been reported with vancomycin?

Friday April 17, 2015  
0715 – 0845

(Registration and Breakfast 0715 – 0740)  
Tupper Room – PEI Convention Centre  
NOTE: Maximum of 50 participants  
(registration required)

**REGISTER NOW**

### Speakers



**Andrew E. Simor**  
MD, FRCPC

Chief, Department of Microbiology  
Chief, Division of Infectious Diseases  
Sunnybrook Health Sciences Centre  
Senior Scientist, Sunnybrook Research Institute  
Professor, Departments of Laboratory Medicine  
& Pathobiology, and Medicine  
University of Toronto,  
Toronto, ON



**Daniel J.G. Thirion**  
BPharm, MSc, PharmD, FCSHP

Clinical Full Professor  
Faculté de pharmacie, Université de Montréal  
Pharmacist, Royal Victoria Hospital/  
McGill University Health Center  
Montréal, QC

### Overall learning objectives

1. Review the evidence that supports vancomycin use in the treatment of complicated MRSA infections.
2. Review the evidence that supports newer agents in the treatment of complicated MRSA infections.
3. Discuss the clinical syndromes of MRSA bacteremia and MRSA pneumonia in the context of vancomycin and newer agents.

### Agenda

- 0715 – 0740 Registration and Breakfast  
0740 – 0745 **Opening Remarks and Introductions**  
0745 – 0750 **Presentation of Cases with Audience Participation**  
Dr Andrew Simor  
0750 – 0810 **Treatment of Serious MRSA Infections: What Alternatives to Vancomycin Should Be Considered?**  
Dr Andrew Simor
- To review current epidemiology of MRSA pneumonia and MRSA bloodstream infection in Canada
  - Discuss why alternative treatments to vancomycin may be considered
- 0810 – 0830 **Why are we still using Vancomycin?**  
Dr Daniel Thirion
- Describe the current evidence supporting the use of vancomycin for treatment of complicated MRSA infections
  - Describe the limits of using vancomycin
- 0830 – 0840 **Return to Cases with Audience Participation**  
Dr Daniel Thirion  
0840 – 0845 **Discussion and Closing remarks**  
Dr Daniel Thirion and  
Dr Andrew Simor



This educational event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada and approved by AMMI Canada. The program was co-developed with AMMI Canada and the Sunovion Pharmaceuticals Canada and was planned to achieve scientific integrity, objectivity and balance. Under the guidance of the Rx&D Code of Ethical Practices this event is for healthcare professionals only.

This program is sponsored by an educational grant from the Sunovion Pharmaceuticals Canada.

